Company Overview
Snapshot
Founded in June 2020 by Prof. Nadir Arber and Dr. Shiran Shapira, Nano24 operates with 1-10 employees. The company has raised $9.5 million across four funding rounds.
Business overview
Nano24 is a biopharmaceutical company focused on developing next-generation immunomodulators to address the cytokine storm, a severe complication in various pulmonary and systemic diseases. The company utilizes CD24 as a drug and Exosomes as a carrier to create EXO-CD24, an exosomal-based drug derived from genetically manipulated human embryonic cells. This platform technology targets unmet medical needs such as Acute Respiratory Distress Syndrome (ARDS), sepsis, and cardiogenic shock, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Log in to access full profile ›Company Intelligence Q&A
- What is Nano24's primary product?
- Nano24's primary product is EXO-CD24, an exosomal-based drug designed to address the cytokine storm by utilizing CD24 as the active drug and Exosomes as the carrier.
- When was Nano24 founded and by whom?
- Nano24 was founded in June 2020 by Prof. Nadir Arber and Dr. Shiran Shapira.
- What is the focus of Nano24's drug development?
- Nano24 focuses on developing immunomodulators to treat the cytokine storm, which is a severe complication associated with various pulmonary and systemic diseases, including ARDS, sepsis, and cardiogenic shock.
- Has Nano24 conducted clinical trials for its product?
- Yes, Nano24 has conducted clinical trials, including phases Ib+IIa and IIb (dose finding study), for EXO-CD24, showing high success in treating the cytokine storm with no deaths and reduced hospitalization duration.